Cerebrolysin — 60mg

Neurotrophic & Neuroprotective Research Compound

Cerebrolysin is a complex preparation of low-molecular-weight peptides and amino acids derived from purified porcine brain proteins. It has been investigated extensively for its potential neurotrophic, neuroprotective, and neurorestorative properties.

Unlike a single-sequence peptide, Cerebrolysin is a multi-component peptide preparation designed to mimic aspects of neurotrophic signaling within the nervous system.

Key Research Areas

• Neuroprotection
• Neuroplasticity
• Neuronal survival
• Cognitive function
• Neurorecovery
• Brain injury research
• Stroke recovery research
• Neurodegenerative disease research

Research has investigated Cerebrolysin in conditions involving neurological injury and cognitive decline, including ischemic stroke, traumatic brain injury, and dementia. Clinical studies and meta-analyses have reported potential improvements in neurological and functional outcomes, although the overall evidence remains mixed and further high-quality research is warranted.

The Science Behind Cerebrolysin

Cerebrolysin’s research profile is centered around neurotrophic signaling and neuronal resilience. Preclinical research suggests it may influence pathways involved in neuronal survival, synaptic plasticity, oxidative stress, and neurogenesis.

The overall research concept can be summarized as:

Neurotrophic Signaling → Neuronal Protection → Neuroplasticity → Neurorecovery

This makes Cerebrolysin particularly interesting for researchers investigating brain health, cognitive function, neuronal resilience, and recovery following neurological stress or injury.

Clinical Research

Cerebrolysin has been studied in human clinical trials, particularly in stroke and traumatic brain injury. A 2025 meta-analysis of 14 randomized controlled trials involving 2,884 patients reported improved neurological recovery after acute ischemic stroke, although functional independence did not reach statistical significance.

Importantly, systematic reviews have reached different conclusions, with a Cochrane review finding insufficient evidence for meaningful clinical benefit in acute ischemic stroke and raising uncertainty regarding non-fatal serious adverse events.

Important Research Note

Cerebrolysin is not a conventional single-molecule peptide. Commercial pharmaceutical Cerebrolysin contains approximately 215.2 mg/mL of porcine brain-derived peptide preparation, so a product labeled 60mg should not be assumed to be equivalent to a standard pharmaceutical Cerebrolysin formulation without verifying its composition and analytical documentation.

Research Use Only

This product is supplied for laboratory and research purposes only. It is not FDA-approved for use in the United States and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or medical condition.

Stack Science™
Performance. Recovery. Longevity.

For Research Use Only. Not for human consumption.